Our top pick for
Building a portfolio
Cortexyme, Inc is a biotechnology business based in the US. Cortexyme shares (CRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Cortexyme employs 37 staff and has a market cap (total outstanding shares value) of USD$993 million.
|52-week range||USD$26.6612 - USD$58.99|
|50-day moving average||USD$35.4889|
|200-day moving average||USD$40.6492|
|Wall St. target price||USD$66.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.169|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-31.42%|
|Return on equity TTM||-53.42%|
|Market capitalisation||USD$993 million|
TTM: trailing 12 months
There are currently 3.2 million Cortexyme shares held short by investors – that's known as Cortexyme's "short interest". This figure is 1.2% down from 3.3 million last month.
There are a few different ways that this level of interest in shorting Cortexyme shares can be evaluated.
Cortexyme's "short interest ratio" (SIR) is the quantity of Cortexyme shares currently shorted divided by the average quantity of Cortexyme shares traded daily (recently around 395937.46928747). Cortexyme's SIR currently stands at 8.14. In other words for every 100,000 Cortexyme shares traded daily on the market, roughly 8140 shares are currently held short.
However Cortexyme's short interest can also be evaluated against the total number of Cortexyme shares, or, against the total number of tradable Cortexyme shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cortexyme's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Cortexyme shares in existence, roughly 110 shares are currently held short) or 0.2078% of the tradable shares (for every 100,000 tradable Cortexyme shares, roughly 208 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cortexyme.
Find out more about how you can short Cortexyme stock.
We're not expecting Cortexyme to pay a dividend over the next 12 months.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.